Want to see HK:6990 full AI Analyst Report?
Total Valuation
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has a market cap or net worth of HK$106.27B. The enterprise value is HK$96.34B.
Market CapHK$106.27B
Enterprise ValueHK$96.34B
Share Statistics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 176,822,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding176,822,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -9.09%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-9.09%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee894.75K
Profits Per Employee-154.69K
Employee Count2,300
Asset Turnover0.34
Inventory Turnover2.40
Valuation Ratios
The current PE Ratio of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is 688.2. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s PEG ratio is -5.55.
PE Ratio688.2
PS Ratio39.59
PB Ratio16.74
Price to FCF-265.74
Price to Operating Cash Flow160.39
PEG Ratio-5.55
Income Statement
In the last 12 months, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H had revenue of 2.06B and earned -381.97M in profits. Earnings per share was -1.66.
Revenue2.06B
Gross Profit1.48B
Operating Income-466.19M
Pretax Income-355.78M
Net Income-381.97M
EBITDA-249.23M
Earnings Per Share (EPS)-1.66
Cash Flow
In the last 12 months, operating cash flow was 551.52M and capital expenditures -119.57M, giving a free cash flow of 431.95M billion.
Operating Cash Flow551.52M
Free Cash Flow431.95M
Free Cash Flow per Share2.44
Dividends & Yields
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.75
52-Week Price Change-10.15%
50-Day Moving Average493.34
200-Day Moving Average455.62
Relative Strength Index (RSI)38.11
Average Volume (3m)562.64K
Important Dates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H upcoming earnings date is Mar 29, 2027, TBA (Confirmed).
Last Earnings DateAug 17, 2026
Next Earnings DateMar 29, 2027
Ex-Dividend Date―
Financial Position
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H as a current ratio of 5.13, with Debt / Equity ratio of 1.52%
Current Ratio5.13
Quick Ratio4.89
Debt to Market Cap<0.01
Net Debt to EBITDA13.01
Interest Coverage Ratio-75.71
Taxes
In the past 12 months, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has paid 26.19M in taxes.
Income Tax26.19M
Effective Tax Rate-0.07
Enterprise Valuation
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H EV to EBITDA ratio is -313.85, with an EV/FCF ratio of -255.16.
EV to Sales38.01
EV to EBITDA-313.85
EV to Free Cash Flow-255.16
EV to Operating Cash Flow-433.83
Balance Sheet
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has HK$4.77B in cash and marketable securities with HK$81.35M in debt, giving a net cash position of HK$4.69B billion.
Cash & Marketable SecuritiesHK$4.77B
Total DebtHK$81.35M
Net CashHK$4.69B
Net Cash Per ShareHK$26.53
Tangible Book Value Per ShareHK$21.11
Margins
Gross margin is 74.55%, with operating margin of -22.65%, and net profit margin of -18.56%.
Gross Margin74.55%
Operating Margin-22.65%
Pretax Margin-17.29%
Net Profit Margin-18.56%
EBITDA Margin-12.11%
EBIT Margin-16.99%
Analyst Forecast
The average price target for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is HK$642.15, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$642.15
Price Target Upside23.49% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast43.88%
EPS Growth Forecast―